Literature DB >> 20050660

Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines.

Everett M Stone1, Evan S Glazer, Lynne Chantranupong, Paul Cherukuri, Robert M Breece, David L Tierney, Steven A Curley, Brent L Iverson, George Georgiou.   

Abstract

Replacing the two Mn(2+) ions normally present in human Arginase I with Co(2+) resulted in a significantly lowered K(M) value without a concomitant reduction in k(cat). In addition, the pH dependence of the reaction was shifted from a pK(a) of 8.5 to a pK(a) of 7.5. The combination of these effects led to a 10-fold increase in overall catalytic activity (k(cat)/K(M)) at pH 7.4, close to the pH of human serum. Just as important for therapeutic applications, Co(2+) substitution lead to significantly increased serum stability of the enzyme. Our data can be explained by direct coordination of l-Arg to one of the Co(2+) ions during reaction, consistent with previously reported model studies. In vitro cytotoxicity experiments verified that the Co(2+)-substituted human Arg I displays an approximately 12- to 15-fold lower IC(50) value for the killing of human hepatocellular carcinoma and melanoma cell lines and thus constitutes a promising new candidate for the treatment of l-Arg auxotrophic tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20050660      PMCID: PMC2842482          DOI: 10.1021/cb900267j

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  29 in total

1.  Structural and functional importance of first-shell metal ligands in the binuclear manganese cluster of arginase I.

Authors:  Evis Cama; Frances A Emig; David E Ash; David W Christianson
Journal:  Biochemistry       Date:  2003-07-01       Impact factor: 3.162

2.  A sensitive method for the colorimetric determination of urea.

Authors:  R N BEALE; D CROFT
Journal:  J Clin Pathol       Date:  1961-07       Impact factor: 3.411

3.  Design and evolution of new catalytic activity with an existing protein scaffold.

Authors:  Hee-Sung Park; Sung-Hun Nam; Jin Kak Lee; Chang No Yoon; Bengt Mannervik; Stephen J Benkovic; Hak-Sung Kim
Journal:  Science       Date:  2006-01-27       Impact factor: 47.728

4.  Altering the binuclear manganese cluster of arginase diminishes thermostability and catalytic function.

Authors:  L R Scolnick; Z F Kanyo; R C Cavalli; D E Ash; D W Christianson
Journal:  Biochemistry       Date:  1997-08-26       Impact factor: 3.162

5.  Kinetics of carboxypeptidase A. The pH dependence of tripeptide hydrolysis catalyzed by zinc, cobalt, and manganese enzymes.

Authors:  D S Auld; B L Vallee
Journal:  Biochemistry       Date:  1970-10-27       Impact factor: 3.162

6.  Guanidine is a Zn(2+)-binding ligand at neutral pH in aqueous solution.

Authors:  Shin Aoki; Kenta Iwaida; Noriko Hanamoto; Motoo Shiro; Eiichi Kimura
Journal:  J Am Chem Soc       Date:  2002-05-15       Impact factor: 15.419

7.  Whole plasmid mutagenic PCR for directed protein evolution.

Authors:  Ichiro Matsumura; Lori A Rowe
Journal:  Biomol Eng       Date:  2005-06

8.  L-arginine binding to liver arginase requires proton transfer to gateway residue His141 and coordination of the guanidinium group to the dimanganese(II,II) center.

Authors:  S V Khangulov; T M Sossong; D E Ash; G C Dismukes
Journal:  Biochemistry       Date:  1998-06-09       Impact factor: 3.162

Review 9.  Ribonucleases as novel chemotherapeutics : the ranpirnase example.

Authors:  J Eugene Lee; Ronald T Raines
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

10.  pH-sensitive control of arginase by Mn(II) ions at submicromolar concentrations.

Authors:  N J Kuhn; J Talbot; S Ward
Journal:  Arch Biochem Biophys       Date:  1991-04       Impact factor: 4.013

View more
  33 in total

1.  Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts.

Authors:  Evan S Glazer; Everett M Stone; Cihui Zhu; Katherine L Massey; Amir N Hamir; Steven A Curley
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.

Authors:  Everett Stone; Lynne Chantranupong; Candice Gonzalez; Jamye O'Neal; Mridula Rani; Carla VanDenBerg; George Georgiou
Journal:  J Control Release       Date:  2011-10-06       Impact factor: 9.776

3.  Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells.

Authors:  Oula Khoury; Noura Ghazale; Everett Stone; Mirvat El-Sibai; Arthur E Frankel; Ralph J Abi-Habib
Journal:  J Neurooncol       Date:  2015-01-08       Impact factor: 4.130

4.  Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent.

Authors:  Ghenwa Nasreddine; Mirvat El-Sibai; Ralph J Abi-Habib
Journal:  Invest New Drugs       Date:  2019-03-18       Impact factor: 3.850

5.  Hyperpolarized [6-13C,15N3]-Arginine as a Probe for in Vivo Arginase Activity.

Authors:  Andrew Cho; Roozbeh Eskandari; Kristin L Granlund; Kayvan R Keshari
Journal:  ACS Chem Biol       Date:  2019-03-27       Impact factor: 5.100

6.  SCHEMA-designed variants of human Arginase I and II reveal sequence elements important to stability and catalysis.

Authors:  Philip A Romero; Everett Stone; Candice Lamb; Lynne Chantranupong; Andreas Krause; Aleksandr E Miklos; Randall A Hughes; Blake Fechtel; Andrew D Ellington; Frances H Arnold; George Georgiou
Journal:  ACS Synth Biol       Date:  2012-06-15       Impact factor: 5.110

7.  GFP reporter screens for the engineering of amino acid degrading enzymes from libraries expressed in bacteria.

Authors:  Olga Paley; Giulia Agnello; Jason Cantor; Tae Hyun Yoo; George Georgiou; Everett Stone
Journal:  Methods Mol Biol       Date:  2013

8.  Structure and function of non-native metal clusters in human arginase I.

Authors:  Edward L D'Antonio; Yang Hai; David W Christianson
Journal:  Biochemistry       Date:  2012-10-12       Impact factor: 3.162

Review 9.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

Review 10.  Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.

Authors:  Macus Tien Kuo; Niramol Savaraj; Lynn G Feun
Journal:  Oncotarget       Date:  2010-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.